Edition:
India

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

39.50USD
20 Apr 2018
Change (% chg)

$0.10 (+0.25%)
Prev Close
$39.40
Open
$39.10
Day's High
$40.05
Day's Low
$38.95
Volume
94,980
Avg. Vol
262,320
52-wk High
$49.90
52-wk Low
$11.80

Latest Key Developments (Source: Significant Developments)

Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS.ATARA BIOTHERAPEUTICS INC - FIRST RESULTS FROM ATA188 PHASE 1 STUDY IN PATIENTS WITH PROGRESSIVE MS IN FIRST HALF OF 2019.  Full Article

Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics
Friday, 5 Jan 2018 

Jan 5 (Reuters) - CAMBER CAPITAL MANAGEMENT LLC ::CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING.  Full Article

Atara Biotherapeutics prices public offering of 7 mln shares at $18.25 per share
Thursday, 4 Jan 2018 

Jan 3 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.00 MILLION COMMON SHARES PRICED AT $18.25PER SHARE.  Full Article

Atara Biotherapeutics Announces Proposed Offering Of Common Stock
Wednesday, 3 Jan 2018 

Jan 2 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.ATARA BIOTHERAPEUTICS INC - ‍COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF ITS SHARES OF COMMON STOCK​.  Full Article

Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Atara Biotherapeutics Inc ::ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD).ATARA BIOTHERAPEUTICS- RESULTS FROM FIRST TABELECLEUCEL PHASE 3 STUDY TO REACH PRIMARY ENDPOINT ARE EXPECTED TO BE ANNOUNCED IN FIRST HALF OF 2019.ATARA-‍PLANS TO SUBMIT TABELECLEUCEL CMA APPLICATION IN EU FOR PATIENTS WITH RITUXIMAB-REFRACTORY EBV+PTLD POST HEMATOPOIETIC CELL TRANSPLANT IN H1 2019.  Full Article

Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Atara Biotherapeutics Inc ::MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING.  Full Article

Atara Biotherapeutics reports Q3 loss per share $1.02
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Atara Biotherapeutics Inc :Atara Biotherapeutics Inc announces third quarter 2017 financial results and recent highlights.Q3 loss per share $1.02.Q3 earnings per share view $-0.98 -- Thomson Reuters I/B/E/S.Atara Biotherapeutics Inc - ‍cash, cash equivalents and short-term investments as of Sept 30, 2017 totaled $200.2 million.Atara Biotherapeutics Inc - ‍cash, cash equivalents and short-term investments will be sufficient to fund planned operations into Q1 2019​.  Full Article

Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Atara Biotherapeutics Inc :Atara Biotherapeutics announces abstract publication for two MSParis2017 congress presentations, including updated interim results from a phase 1 study of autologous ATA190 in patients with progressive multiple sclerosis (MS).Atara Biotherapeutics Inc - ‍no significant adverse events have been observed in study​.  Full Article

Atara Biotherapeutics reports Q2 loss per share $0.66
Monday, 8 Aug 2016 

Atara Biotherapeutics Inc : Atara bio announces second quarter 2016 financial results and recent highlights . Q2 loss per share $0.66 . Q2 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S .Cash, investments as of June 30 totaled $294.6 million, which co believes to be sufficient to fund planned operations through 2018.  Full Article